ADHD
Psychiatry· 9 reviewed drugs· 4558 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library cover several drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). These include Qelbree (viloxazine ER), indicated for pediatric patients 6 to 17 years of age, which showed an ADHD-RS-5 Total Score LS Mean Difference from Placebo (SPN-812 ER 200 mg/day) of -7.8. Azstarys, indicated for patients ages 6 years and older, demonstrated a SKAMP combined score change from baseline (LS mean difference) of -5.4. COTEMPLA XR-ODT, for children aged 6-12 years, reported SKAMP-Combined scores LS mean difference vs placebo of -11.0. Jornay Pm, for ADHD treatment, showed a SKAMP score mean difference (HLD200 vs placebo) of -5.9. It is important to note that these figures are derived from different trials and are not directly comparable head-to-head.
The drugs — one cited result each
| Qelbree / viloxazine ER Supernus Pharmaceuticals, Inc. | ADHD-RS-5 Total Score LS Mean Difference from Placebo (SPN-812 ER 200 mg/day): -7.8 Supernus Pharmaceuticals, Inc. — Qelbree FDA Review (NDA2119, p.239 |
| Azstarys COMMAVE SUB | SKAMP combined score change from baseline (LS mean difference): -5.4 COMMAVE SUB — Azstarys FDA Review, p.5 |
| Xelstrym NOVEN PHARMS INC | Cmax LS GeoMean Ratio d-ATS/Vyvanse: 66.6 % NOVEN PHARMS INC — Xelstrym FDA Review (NDA215401, ORIG 1, 2, p.178 |
| Slenyto RAD Neurim Pharmaceuticals | 580 cited findings on the drug page → |
| Jornay Pm Ironshore Pharmaceuticals | SKAMP score mean difference (HLD200 vs placebo): -5.9 Ironshore Pharmaceuticals — Jornay Pm FDA Review (NDA209311,, p.7 |
| COTEMPLA XR-ODT NEOS THERAPS INC | SKAMP-Combined scores LS mean difference vs placebo: -11.0 NEOS THERAPS INC — Cotempla Xr-Odt FDA Review (NDA205489, OR, p.26 |
| Dyanavel XR Tris Pharma | Duration of clinical efficacy for Amphetamine ER tablets: one hour to 13 hours Tris Pharma — Dyanavel Xr FDA Review (NDA210526, ORIG 1, 202, p.32 |
| Tuzulby Neuraxpharm | SKAMP-Combined score (LS mean) change from placebo: -7.0 Neuraxpharm — Tuzulby EMA EPAR variation assessment report, p.61 |
| Onyda XR Tris Pharma | Deaths: 0 Tris Pharma — Onyda Xr FDA Review, p.44 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Psychiatry research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.